Connor, Clark & Lunn Investment Management (CC&L)’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,193	Closed	-$147K	–	985
2017 Q1	$147K	Buy	+1,193	New	+$156K	﹤0.01%	827
2015 Q4	–	Sell	-1,430	Closed	-$208K	–	886
2015 Q3	$208K	Buy	+1,430	New	+$262K	﹤0.01%	641

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BLCM Position: Q2 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 1,193 shares — an estimated $147K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BLCM in Q3 2015 and held it in 2 quarters. The position peaked at $208K in Q3 2015. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 1,193 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $147K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Bellicum Pharmaceuticals, Inc. position peaked at $208K in Q3 2015.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2017, filed 14 Aug 2017.